Tricuspid percutaneous transcatheter edge to edge repair (TEER) is safe in patients with severe tricuspid regurgitation, and reduces the severity of tricuspid regurgitation and is associated with improvement in quality of life.
For patient with severe tricuspid regurgitation, transcatheter tricuspid valve replacement is superior to medical therapy alone for the primary composite outcome, driven primarily by improvement in symptoms and quality of life (TRISCEND).
TEER involves a transvenous approach, and approximates the tricuspid valve leaflets by deploying a clip to hold the leaflet together and reduce tricuspid regurgitation without the need for cardiopulmonary bypass or cardiac surgery.
TEER reduces, tricuspid, regurgitation, alleviate symptoms, reduces, neurohormonal activation, and induces reverse modeling of the right heart, compared with medical therapy alone:but this trial did not show difference in the incident of death or hospitalization for heart failure at one year, suggesting that coexisting conditions are primary determinants of outcome.
TEER is the most common transcatheter therapy worldwide.
TEER compared to medically treated patients is associated with the lower incidence of the composite end point of death and rehospitalization.
Metaanalysis showed mortality rate of 5% for the TEER procedure at 30 days, and an overall mortality of 25% at one year.
TEER devices can reduce tricuspid regurgitation to moderate or less than 80 to 85% of patients and two mild or less and only 30 to 50% of patients.
Transcatheter edge to edge repair reduces, tricuspid regurgitation severity, and improves patient reported outcome measures in patients with severe symptomatic tricuspid regurgitation (Tri-Fr investigators).